Floatz logo

Cytosin-Arabinosid

Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication

First Affiliated Hospital of Zhejiang UniversityPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
Quizartinib
M.D. Anderson Cancer Center
Phase 2BB
Daunorubicin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB

View all 21 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →